Immix Biopharma (IMMX) Q3 2026 earnings summary

Executive summary

• NEXICART-2 enrollment completed at 45 patients; September data showed 40 complete responses (89%), with four MRD-negative patients awaiting CR status and potential to reach 44/45 (98%).

• Launch preparation continued across commercial site activation, provider and payer engagement, manufacturing, and healthcare professional education.

• Interim NEXICART-2 results were selected for an oral presentation at ASH 2026.

Financial highlights

• Q3 2026 operating expenses were $15.9M, including $10.4M in R&D and $5.5M in G&A, versus $7.7M a year earlier; net loss was $13.9M versus $7.6M.

• 9M 2026 operating expenses were $39.2M versus $19.1M a year earlier; net loss was $35.6M versus $18.8M.

• Interest income was $2.0M in Q3 and $3.6M in 9M 2026, versus $0.1M and $0.3M, respectively, a year earlier.

• No product-sales revenue; Q3 basic and diluted loss per share was $0.19 versus $0.24, while 9M loss per share was $0.55 versus $0.61.

Outlook and guidance

• Planned BLA submission is mid-2027; NEXICART-3 frontline trial initiation is planned for H1 2027.

• Cash, cash equivalents, and marketable securities were expected to fund operations into mid-2028; the filing separately stated cash, cash equivalents, and short-term investments would fund operations for at least 12 months from its filing date.

• NEXICART-2 interim data were scheduled for presentation at ASH on December 14, 2026; a presentation was also planned at the J.P. Morgan Healthcare Conference, January 11–14, 2027.

• Expenses and operating losses are expected to rise as clinical programs expand; additional capital is expected to be needed beyond the stated runway.